A treatment that could neutralise the harmful protein particles that cause Alzheimer's disease has been developed in the US.
Researchers at the Rensselaer Polytechnic Institute (RPI) in New York explained a process that involves designing antibodies could target the Alzheimer's protein and prevent it from leading to the onset of the condition.
The study, published in the journal Proceedings of the National Academy of Sciences, utilised the same molecular interactions that result in the Alzheimer's proteins sticking together and forming the toxic particles that are associated with the disease.
"By binding to specific portions of the toxic protein, we could test hypotheses about how to prevent or reverse cellular toxicity linked to Alzheimer's disease," explained lead researcher Peter Tessier, assistant professor of chemical and biological engineering at the RPI.
According to the Brain Research Trust, approximately 700,000 people in the UK suffer from Alzheimer's disease, including about one in 14 people aged over 65 and a sixth of over-80s.